Keeping the pipeline of new stents, pacemakers, and catheters fresh is especially important because heart-related items account for 80 percent of Boston Scientific’s sales. Over the past few years, engineers have been focused on quality system improvements, Currier says. Boston Scientific had inherited regulatory problems from acquisitions it made during that time. Now that those situations are addressed, the company is ready to reinvigorate internal innovation.